Also known as: Malaria (Plasmodium Infection)
Malaria is a serious, potentially life-threatening mosquito-borne parasitic disease caused by Plasmodium parasites. It remains one of the world's most significant infectious diseases.
Malaria causes an estimated 249 million cases and 608,000 deaths annually, mostly among children under 5 in Sub-Saharan Africa. It is transmitted through the bite of infected female Anopheles mosquitoes.
Five species of Plasmodium cause human malaria, with P. falciparum being the most deadly and P. vivax the most widespread. After entering the body, the parasites multiply in the liver before infecting red blood cells.
Malaria is preventable through mosquito bite prevention, prophylactic medication, and now vaccination. The RTS,S and R21 vaccines represent major breakthroughs in malaria prevention. Treatment with artemisinin-based combination therapy is highly effective when started early.
People with Malaria often experience the following symptoms.
Classic cyclical episodes of cold stage (rigors and chills), hot stage (high fever up to 41°C), and sweating stage, recurring every 48–72 hours depending on the species.
Headache, muscle aches, fatigue, nausea, and vomiting are common during acute infection, resembling a severe flu.
Destruction of red blood cells by the parasite leads to progressive anaemia, causing pallor, weakness, and shortness of breath.
Confusion, seizures, respiratory distress, severe anaemia, dark urine (blackwater fever), and multi-organ failure indicate complicated malaria requiring urgent treatment.
Certain factors may increase your likelihood of developing Malaria.
Common approaches to managing malaria. Always consult a healthcare provider for personalized treatment.
ACTs are the first-line treatment for uncomplicated P. falciparum malaria. Combinations like artemether-lumefantrine are highly effective.
Still effective for P. vivax, P. ovale, and P. malariae in most regions. P. falciparum is widely resistant to chloroquine.
Required to eliminate dormant liver-stage parasites (hypnozoites) in P. vivax and P. ovale infections to prevent relapse.
The treatment of choice for severe malaria, administered intravenously in a hospital setting.
Diagnosis is confirmed by microscopic examination of blood smears (thick and thin films) or rapid diagnostic tests (RDTs) that detect parasite antigens. Species identification is important for guiding treatment. PCR testing is available for confirmation.
Seek immediate medical attention if you develop fever within 2 months of travelling to a malaria-endemic area, especially if accompanied by confusion, severe headache, difficulty breathing, or dark urine.
Steps that may help reduce the risk of developing or worsening malaria.
Antimalarial prophylaxis when travelling to endemic areas
Insecticide-treated bed nets
DEET-containing insect repellent
Vaccination (RTS,S or R21 for children in endemic areas)
If left untreated or poorly managed, malaria may lead to:
Yes, malaria is curable with appropriate antimalarial treatment. However, P. vivax and P. ovale can relapse from dormant liver stages if not treated with primaquine or tafenoquine.
The incubation period is typically 7–30 days depending on the species. P. falciparum tends to cause symptoms sooner (7–14 days), while P. vivax may take longer or even remain dormant for months.
This depends on your destination. Consult a travel medicine specialist at least 4–6 weeks before departure. They will assess the malaria risk at your destination and recommend appropriate prophylaxis if needed.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.